Prelude Therapeutics details 2026 shareholder voting results
Prelude Therapeutics Incorporated reported results of its 2026 Annual Meeting of Stockholders held on June 9, 2026.
Rhea-AI Filing Summary
Prelude Therapeutics Incorporated reported results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. Stockholders elected three Class III directors—Krishna Vaddi, Paul Scherer, and Katina Dorton—to terms expiring at the 2029 annual meeting, each receiving over 25 million votes in favor.
Investors also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 31,841,080 shares voting for and minimal opposition. In advisory votes, stockholders approved 2025 executive compensation and indicated a preference to hold say-on-pay votes every one year.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for Vaddi: 26,996,820 shares
Votes for Scherer: 25,532,267 shares
Votes for Dorton: 26,998,601 shares
+3 more
6 metrics
Votes for Vaddi
26,996,820 shares
Election of Class III director Krishna Vaddi, Ph.D.
Votes for Scherer
25,532,267 shares
Election of Class III director Paul Scherer, MD, Ph.D.
Votes for Dorton
26,998,601 shares
Election of Class III director Katina Dorton, J.D., MBA
Auditor ratification for
31,841,080 shares
Ratification of Ernst & Young LLP for fiscal year 2026
Say-on-pay approval
26,869,142 shares for
Advisory vote on 2025 executive compensation
Annual frequency support
26,877,941 shares
Preference for one-year say-on-pay frequency
Key Terms
broker non-votes, independent registered public accounting firm, advisory vote, emerging growth company, +1 more
5 terms
broker non-votes financial
"Nominees | | Shares For | | Shares Withheld | | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
advisory vote financial
"Advisory vote to approve the 2025 compensation for the Company's named executive officers"
An advisory vote is a shareholder poll that expresses investors’ approval or concern about a company’s policy, executive pay, board decisions or other governance matters but does not legally force the company to act. Think of it like a customer survey: it signals investor sentiment and can pressure management to change course, so investors watch the result as a guide to future governance, risk and potential shifts in strategy.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Annual Meeting of Stockholders financial
"held its 2026 Annual Meeting of Stockholders (the "Annual Meeting")"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Prelude Therapeutics (PRLD) stockholders vote on at the 2026 annual meeting?
Stockholders voted on electing three Class III directors, ratifying Ernst & Young LLP as auditor for 2026, approving 2025 executive compensation, and setting the frequency of future say-on-pay votes. All four proposals received sufficient support to be approved.
Which directors were elected at Prelude Therapeutics (PRLD) 2026 annual meeting?
Stockholders elected Krishna Vaddi, Paul Scherer, and Katina Dorton as Class III directors. Each will serve a three-year term expiring at the 2029 annual meeting, continuing until a successor is elected and qualified or earlier resignation or removal under the company’s governance framework.
How did Prelude Therapeutics (PRLD) investors vote on the 2025 executive compensation proposal?
The advisory vote on 2025 executive compensation passed, with 26,869,142 shares for, 107,500 against, and 76,115 abstaining, plus 4,799,016 broker non-votes. This non-binding vote indicates broad stockholder support for the company’s named executive officer pay program for 2025.
What auditor did Prelude Therapeutics (PRLD) stockholders ratify for fiscal year 2026?
Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received 31,841,080 shares for, 4,951 against, 5,742 abstaining, and no broker non-votes, indicating strong support for the auditor choice.
What frequency of say-on-pay votes did Prelude Therapeutics (PRLD) stockholders prefer?
In the advisory vote on frequency of say-on-pay votes, 26,877,941 shares favored one year, 65,638 favored two years, 103,237 favored three years, and 5,941 abstained, with 4,799,016 broker non-votes. This outcome shows a clear stockholder preference for annual advisory compensation votes.
How many votes did each Prelude Therapeutics (PRLD) director nominee receive?
Krishna Vaddi received 26,996,820 shares for and 55,937 withheld; Paul Scherer 25,532,267 for and 1,520,490 withheld; Katina Dorton 26,998,601 for and 54,156 withheld. Each nominee also had 4,799,016 broker non-votes recorded in the director election tally.
AI-generated analysis. How Rhea-AI works. Not financial advice.
